Compare Adaptive Biotechnologies Corp (ADPT) vs Hut 8 Corp (HUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Hut 8 Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Hut 8 Corp trades at $98.99 (market cap $10.89B). The key difference: Hut 8 Corp is far larger — about 3.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | HUT | |
|---|---|---|
Market Cap | $3.33B | $10.89B |
Sector | Health | Technology |
52-Week High | $22.37 | $133.02 |
52-Week Low | $10.24 | $19.45 |
Enterprise Value | $3.19B | $11.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HUT trades at $103.78, up 6.84% today, but faces bearish technical signals with resistance at $108. The company shows strong analyst support (93.75% buy ratings) with a $129.44 consensus target, yet fundamentals reveal challenges: negative net income margin of -109.77% in 2025 and operating cash flow of -$139.23M. Recent news highlights Hut 8's pivot to AI infrastructure, closing $4.25B in project financing for data centers, signaling strategic growth amid profitability concerns.
Outlook: High growth potential from AI/data center expansion, but elevated execution risks and persistent losses warrant caution. Near-term price movement may hinge on Q2 2026 earnings (expected EPS -$0.32) and Bitcoin market volatility. Risks include competitive pressures and reliance on financing for cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
